A Study to Evaluate the Safety of TRV130 in Patients who have Acute Pain

Overview

About this study

The purpose of this study is to evaluate the safety of TRV130 for treatment of patients who have moderate to severe pain caused by medical conditions or surgery, and who require IV opioid therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Moderate to severe acute pain for which parenteral opioid therapy is warranted
  • Able to understand and comply with the procedures and study requirements
  • Able to provide written informed consent before any study procedure

Exclusion Criteria

  • Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that would confound the interpretation of safety, tolerability, or efficacy data in the study
  • Hemodynamic instability or respiratory insufficiency
  • Advanced cancer in palliative or end-of-life care
  • Another current painful condition (other than acute pain for which parenteral opioid therapy is warranted) that would confound the interpretation of safety, tolerability, or efficacy data in the study
  • Clinically significant, immune-mediated hypersensitivity reaction to opioids

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

John Leslie, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20318090

Mayo Clinic Footer